Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list

Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome

(2017) El-Sayed Ibrahim et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure

(2016) Joan Clària et al.   HEPATOLOGY

Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial

(2016) Nina Kimer et al.   HEPATOLOGY

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

(2016) James G. Orr et al.   LIVER INTERNATIONAL

Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure–Sequential Organ Failure Scoring System

(2015) Mark J.W. McPhail et al.   Clinical Gastroenterology and Hepatology

Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis

(2015) Thierry Gustot et al.   HEPATOLOGY

Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study

(2015) Xin Zeng et al.   Journal of Digestive Diseases

Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?

(2015) Debbie L Shawcross   Expert Review of Gastroenterology & Hepatology

Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization

(2014) Kavish R Patidar et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

(2014) Rajiv Jalan et al.   JOURNAL OF HEPATOLOGY

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

(2013) Kevin D. Mullen et al.   Clinical Gastroenterology and Hepatology

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

(2013) Richard Moreau et al.   GASTROENTEROLOGY

Increased risk of cognitive impairment in cirrhotic patients with bacterial infections

(2013) Manuela Merli et al.   JOURNAL OF HEPATOLOGY

Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF)

(2013) Juan Cordoba et al.   JOURNAL OF HEPATOLOGY

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

(2013) Jasmohan S. Bajaj et al.   PLoS One

The impact of organ dysfunction in cirrhosis: Survival at a cost?

(2012) Debbie L. Shawcross et al.   JOURNAL OF HEPATOLOGY

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study

(2011) A. Sanyal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hospital Readmissions Among Patients With Decompensated Cirrhosis

(2011) Michael L Volk et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis

(2011) Georgios N. Kalambokis et al.   HEPATOLOGY

Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis

(2010) Vasiliki Arvaniti et al.   GASTROENTEROLOGY

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis

(2010) D.L. Shawcross et al.   JOURNAL OF HEPATOLOGY

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course of alcoholic liver cirrhosis: A Danish population-based cohort study

(2009) Peter Jepsen et al.   HEPATOLOGY